A randomized, multicenter phase III study of lobaplatin/etoposide versus cisplatin/etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer and circulating tumor cells (CTCs) as an exploratory biomarker.
Ying Cheng
No relevant relationships to disclose
Yun Fan
No relevant relationships to disclose
Xiaoqing Liu
No relevant relationships to disclose
Yunpeng Liu
No relevant relationships to disclose
Jiwei Liu
No relevant relationships to disclose
Dong Wang
No relevant relationships to disclose
Yan Yu
No relevant relationships to disclose
Shukui Qin
No relevant relationships to disclose
Wei Liu
No relevant relationships to disclose
Cheng Huang
No relevant relationships to disclose
Helong Zhang
No relevant relationships to disclose
Jun Liang
No relevant relationships to disclose
Jianhua Shi
No relevant relationships to disclose
Lijun Sheng
No relevant relationships to disclose